Bayer Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Bayer Healthcare Aktiengesellschaft

Karl Ziegelbauer

Toshiki Murata

Tsutomu Masuda

Takuya Shintani

Kinji Fuchikami

Hiroshi Komura

Masaomi Umeda

Yuji Koriyama

Hiroki Sato

Sachiko Sakakibara

Hiroshi Kadono

Timothy B Lowinger

Gerhard Hessler

Takashi Yoshino

Mitsuyuki Shimada

Masaomi Tajimi

Markus Albers

Thomas Lehmann

Haruki Hasegawa

Hiromi Okigami

Rüdiger Fischer

Thomas Rölle

Joachim Mittendorf

Franz Kunisch

Hans-Christian Militzer

Michael Matzke

Timothy Lowinger

Wolfgang Schonfeld

Axel Schmidt

Takashi Yoshiro

Mitsuiyuki Shimada

Olaf Weber

Kevin Bacon

Nagahiro Yoshida

Kevin B Bacon

Gerhard M&uuml;ller

Gerhard Müller

Thomas R&ouml;lle

Sachiko Sasaki

Yuka Ikegami

Makoto Shimazaki

The present invention relates to pharmaceutical compositions and combinations comprising regorafenib and acetylsalicylic acid, or a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof or a polymorph thereof for treating, preventing or managing diseases and conditions including hyperproliverative disorders such as cancer in humans and other mammals.

Combination of regorafenib and acetylsalicylic acid for treating cancer

Pyrimidine compounds of general formula: wherein &#x2014;Rrepresents in which Ris hydrogen, Calkyl, halogen, hydroxy, Calkoxy, nitro, amino, Calkylsulfonylamino, Calkoxycarbonyl, Calkylamino, di (Calkyl)amino, Calkanoylamino, phenyl Calkylamino, phenylsulfonylamino, or &#x2014;O&#x2014;(CH)&#x2014;R; Rrepresents hydrogen or halogen; Rrepresents hydrogen, &#x2014;CRRR; Ris hydrogen, carbamoyl, CN, carboxyl, etc.; Ris amino, Calkylamino, di Calkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.

Pyridine derivatives

4-aryl pyrimidine compounds of general formula and salts thereof: wherein X is CH or N; R1 is hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, etc.; R2 is hydrogen or hydroxy; R3 is hydrogen, C1-6 alkyl, etc.; R4 is hydrogen, hydroxy, halogen, amino, etc.; R5 is hydroxy, amino, carboxy, etc.; R6 is hydrogen, carbamoyl, cyano, carboxy, C1-6 alkoxycarbonyl, etc. and R7 is amino or C1-6 alkanoylamino. The compounds (I) or the salts thereof have an excellent anti-inflammatory activity and the like.

4-6-diphenyl pyridine derivatives as antiinflammatory agents

This invention is to provide a process for producing 2-amino-4,6-disubstituted nicotinic acid ester analogs and salts thereof, comprising the reaction shown by the following scheme. The ester analogs can be prepared in one pot, and in good yield by using tertiary alkyl cyanoacetate. Furthermore, the method is useful for preparing derivatives of various analogs of the ester, e.g. alkyl substituted and aryl substituted analogs. 

The present invention relates to compounds of the general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of inflammatory diseases.

Beta-amino acid derivatives as integrin receptor antagonists

The present invention relates to compounds of the general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of inflammatory diseases 

Succinic acid derivatives

Pyridine compounds of general formula:wherein &#x2014;Rrepresentsin which Ris hydrogen, Calkyl, halogen, hydroxy, Calkoxy, nitro, amino, Calkylsulfonylamino, Calkoxycarbonyl, Calkylamino, di (Calkyl)amino, Calkanoylamino, phenyl Calkylamino, phenylsulfonylamino, or &#x2014;O&#x2014;(CH)&#x2014;R; Rrepresents hydrogen or halogen; Rrepresents 1.2.3.6-tetrahydro-pyridine, or &#x2014;CRRRwherein Rrepresents H or Calkyl and Rand Rare joined to form a 5-8 membered saturated ring optionally containing up to three heteroatoms; Ris carbamoyl, CN, carboxyl, etc.; Ris amino, Calkylamino, di Calkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.

&bgr;-amino acid compounds as integrin antagonists

The present invention relates to mixtures of .alpha.-amino acids and/or derivatives thereof and cyclopentane-.beta.-amino acids and/or derivatives thereof, dipeptides of the abovementioned .alpha.-amino acids and cyclopentane-.beta.-amino acids and mixtures of the abovementioned mixtures and dipeptides which have an improved tolerability in warm-blooded animals compared with the pure cyclopentane-.beta.-amino acids.

Tolerability of pharmaceutically active .beta.-amino acids

The present invention relates to cyclopentane-.beta.-amino acid tripeptides, a process for their preparation and their use as antimicrobial, in particular antimycotic, medicaments.

Cyclopentane-.beta.-amino acid tripeptides

Growing community of inventors

Haan, Germany

Karl Ziegelbauer